Technical Analysis for CDTX - Cidara Therapeutics, Inc.

Grade Last Price % Change Price Change
grade F 2.56 0.39% 0.01
CDTX closed up 0.39 percent on Wednesday, March 20, 2019, on 38 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Up
See historical CDTX trend table...

Date Alert Name Type % Chg
Mar 20 Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
Mar 20 NR7 Range Contraction 0.00%
Mar 20 NR7-2 Range Contraction 0.00%
Mar 20 Doji - Bearish? Reversal 0.00%
Mar 20 Wide Bands Range Expansion 0.00%
Mar 20 Up 3 Days in a Row Strength 0.00%
Mar 20 Up 4 Days in a Row Strength 0.00%
Mar 19 Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.39%
Mar 19 NR7 Range Contraction 0.39%
Mar 19 Wide Bands Range Expansion 0.39%

Older signals for CDTX ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Cidara Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of novel anti-infectives for the treatment of diseases. Its lead product candidate is CD101 IV, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of systemic Candida infections. The company also develops CD101 topical, a topical formulation of CD101 for the treatment of recurrent vulvovaginal candidiasis, a prevalent mucosal infection. In addition, it develops a proprietary immunotherapy technology platform, Cloudbreak, which is used to create compounds designed to direct a patient's immune cells to attack and eliminate pathogens that cause infectious disease. Cidara Therapeutics is developing its first Cloudbreak development candidate, C001, for the treatment of invasive aspergillosis; and evaluating additional opportunities to expand its Cloudbreak immunotherapy platform to other areas of infectious disease. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in June 2014. Cidara Therapeutics, Inc. was founded in 2012 and is based in San Diego, California.
Biopharmaceutical Medical Specialties Diseases Infectious Diseases Immunotherapy Infectious Disease Anti Infectives Immunotherapy Technology
Is CDTX a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 6.35
52 Week Low 1.94
Average Volume 79,749
200-Day Moving Average 3.8018
50-Day Moving Average 2.7508
20-Day Moving Average 2.635
10-Day Moving Average 2.464
Average True Range 0.226
ADX 14.94
+DI 21.2755
-DI 15.2772
Chandelier Exit (Long, 3 ATRs ) 2.522
Chandelier Exit (Short, 3 ATRs ) 2.878
Upper Bollinger Band 3.0408
Lower Bollinger Band 2.2292
Percent B (%b) 0.41
BandWidth 30.800759
MACD Line -0.0746
MACD Signal Line -0.0728
MACD Histogram -0.0017
Fundamentals Value
Market Cap 43.17 Million
Num Shares 16.9 Million
EPS -3.55
Price-to-Earnings (P/E) Ratio -0.72
Price-to-Sales 0.00
Price-to-Book 2.16
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 2.76
Resistance 3 (R3) 2.76 2.69 2.72
Resistance 2 (R2) 2.69 2.64 2.69 2.71
Resistance 1 (R1) 2.63 2.61 2.66 2.63 2.70
Pivot Point 2.56 2.56 2.58 2.56 2.56
Support 1 (S1) 2.50 2.51 2.53 2.50 2.42
Support 2 (S2) 2.43 2.48 2.43 2.41
Support 3 (S3) 2.37 2.43 2.40
Support 4 (S4) 2.37